


NIFTY KEY LEVELS

Support 1 : 11035
Support 2 : 10950
Resistance1:11180
Resistance2:11250

Nifty Intraday Chart



Market Outlook

Yesterday, Nifty opened positive at 11231.20 level and rallied towards the high of 11238.10 levels. It faced resistance at its high and slipped towards the low of 11056.55 level and managed to closed at 11132.60 levels. Nifty sector indices traded mix as MEDIA, PHARMA and PVT BANK traded and closed positive, while rest of the indices closed with negative bias. India VIX closed positive by 1.87% to 24.88.

After four days of straight buying, index took a breather as profit booking is seen at our mentioned resistance of 11250 level. Nifty reversed its course of action as it negated the higher low formations but some recovery is seen in the last hour of trade which turned the daily candle into hanging man. The levels of 11180 and 11250 acting as overhead resistance points. The supports come in at 11035 and 10950 levels.

Indian Market

Index (Prev. Close)	Value	% Change
SENSEX	37,871.52	-0.16%
NIFTY	11,132.60	-0.27%
BANK NIFTY	22,882.60	0.44%

Global Market

Index (Prev. Close)	Value	% Change
DOW	27,005.84	0.62%
NASDAQ	10,706.13	0.24%
CAC	5,037.12	-1.32%
DAX	13,104.25	-0.51%
FTSE	6,207.10	-1.00%
EW ALL SHARE	18,558.02	-0.24%

Morning Asian Market (8:30 am)

SGX NIFTY	11,119.30	-0.06%
NIKKIE	22,751.61	-0.58%
HANG SENG	25,224.50	0.66%

Commodity Market

Commodity(Prev. Close)	Value	% Change
GOLD	50,078.00	1.11%
SILVER	61,115.00	6.58%
CRUDEOIL	44.31	0.02%
NATURALGAS	126.10	1.45%

Currency Market

Currency (Prev. Close)	Value	% Change
RS./DOLLAR	74.76	0.02%
RS./EURO	86.10	0.77%
RS./POUND	94.58	-0.27%

Bond Yield

Bond yield (Prev. Close)	Value	% Change
G-sec 10YR : IND	5.81	-0.26%

% Change in 1 day

Institutional Turnover

FII			
Investor	Buy(Cr.)	Sale(Cr.)	Net(Cr.)
22-Jul-20	6909	5243	1666
Jul-20	75818	74167	1651
2020	885991	954790	(68799)
DII			
Investor	Buy(Cr.)	Sale(Cr.)	Net(Cr.)
22-Jul-20	3695	4833	(1139)
Jul-20	59610	65237	(5628)
2020	672389	587936	84453

Events Today

Dividend

CGCL
SOBHA
ORIENTCEM
AKCAPIT
ASIANPAINT
MAHLOG
SUPER
TECHM
TIMKEN
HCLTECH

Right Issue

GDL
Ex - Date: 23/07/2020

Results

ABB
AUBANK
BIOCON
DISHTV
MPHASIS
PNBHousing
RADICO
SKFINDIA
STRTECH
ARENTERP

Please refer to page pg 08 for Bulk deals, Dividends, Bonus, Splits, Buyback.

Quote of the Day : "In investing, what is comfortable is rarely profitable."

BAJAJ-AUTO**BUY****23-Jul-20**

Domestic motorcycle market is expected to recover in next couple of quarters considering the demand reaching to 75% of last year levels. However, lockdowns in several cities and metros may have negative impact on volumes in near term. Market share in overall domestic motorcycle market improved from FY20 by 220bps to 20.7% in 1QFY21. Further the management has indicated that there is no downtrading within the segment. International market has also recovered well and volumes in majority of the key markets have reached to 75-80% of previous year levels. Going ahead the management plans to enter in Brazil market with the premium offerings. We largely maintain our FY21 estimates. We value BAJAJ-AUTO at 18x FY22e EPS and maintain our previous target price of Rs.3618 and continue with BUY rating.

HINDUNILVR**HOLD****23-Jul-20**

In 1QFY21, HINDUNILVR numbers remained positive while volumes remained under stress due to stress in discretionary portfolio. The Company is witnessing higher demand in its food and refreshment, homecare, hygiene and nutrition categories are expected to perform better led by increased in-home consumption, consumer higher divergence towards sanitization and increased use of immunity boosting element. Going forward distribution will remain the concern due to extension of regional lock downs amidst rising COVID cases. On margin front, the company is witnessing input inflation in some of the key inputs like tea, tomato paste, veg. oil while benign crude and SMP prices coupled with judicious price hike will provide some cushion to margins. Employee expense are expected to remain high level due to high employee cost on nutrition business while A&P is expected to remain at a reduced level amidst pandemic. Going forward, we remain positive on the stock in long-run. However, considering the current scenario of increasing rate of spread of disease and local lock downs we have maintained HOLD rating with a target price of Rs. 2350

HINDZINC**NEUTRAL****23-Jul-20**

HINDZINC muted mined metal production guidance for FY21 based on subdued demand. LME prices rebound from May onwards from years low in the month of March. Management is confident for the silver production volumes along with the increase in the prices of silver. Higher employee cost due to lower mined metal volumes reduced margins. However, higher other income and reduced tax rates offset PAT margin. We maintain our stance to remain NEUTRAL at Rs. 211 13.5x EV/EBITDA FY21E.

AXISBANK**BUY****22-Jul-20**

NII during the quarter grew healthy led by reduction in cost of funds however the operating profit was down by 1% YoY due to lower fee income. The asset quality improvement for the bank continued with slippages moderating on account of moratorium. The moratorium book has declined from around 25% in March to 10% in June BB and below book was largely stable Sequentially. 82% of the corporate book is A or above rated while the 96% incremental sanctions were rated A or above Advance and deposit registered sequential De-growth impacted on account of lockdown. Bank has made the accounting policy change which has impacted its profitability. The PCR of the bank is strong at 75% while the Tier 1 capital stood at 17.5% which puts it in strong position to face situation ahead. Bank also has an enabling resolution to raise capital worth Rs 15000 Cr which can be raised as the situation required. Going forward trend in Moratorium book will be a key trackable. We maintain Buy with TP of Rs 586 at 1.8XBVFY21E

BAJFINANCE**NEUTRAL****22-Jul-20**

AUM growth remained muted in fact declined QoQ for the first time in the history. The Company estimates AUM growth to be low at 10-12% for FY21. However, it is focusing on taking a cautious stance and tightened 2020 OPEX is reducing and is expected to be reduced by controlling the discretionary expenses and holding on to the expansion plans. Focus on maintaining liquidity buffer, risk management while strengthening the balance sheet will help the company go ahead. The company revised the credit cost guidance to be at 100-110% higher than last year for FY21. So on the account of lower AUM growth as well as high credit cost but Lower OPEX We value the stock at 5.4 x P/BV FY21E with Neutral rating at target price of Rs 3125.

- ❑ US markets ended positive with gains on 0.5%
- ❑ Dow Jones Closing above 27000 after 6 weeks
- ❑ SGX Nifty Fut trading at 11152 up 22 pts @ 7.30 am IST today
- ❑ Asian markets trades mixed: HangSeng positive while Korea negative
- ❑ Crude prices keep moving high: Brent above 44\$ while WTI near 42\$ per bbl
- ❑ Silver up 17% in this week; Gold trades at multiyear highs
- ❑ US China tensions increase has created worry in Asian markets
- ❑ Hopes of vaccine for Covid-19 keeps mkts trade higher
- ❑ Y'day in cash seg: FII bought worth 1666 crs while DIIs sold worth 1139
- ❑ FII bought 6339 crs and turned buyers for July 2020
- ❑ Nifty July Fut trades at 22.05 pts discount vs 8.3 pts premium
- ❑ In FNO Seg: FII added 3651 long contracts in Index Futures
- ❑ In Options: FII bought 17911 Put contracts and wrote 8000 Put and Calls
- ❑ Nifty PCR stands at 1.67 vs 1.87
- ❑ Nifty yesterday low 11057 and high 11238 critical to watch
- ❑ For short sellers, yesterday high will stoploss
- ❑ Sensex and Nifty snaps 5-day gaining streak
- ❑ Markets may have extremely heavy volatility; Don't trade without stoploss
- ❑ Delivery buying seen yesterday in Axisbank 1000 crs, RIL 1800 crs and ICICIBank 500 crs
- ❑ L&T weak operational performance; Order inflow down 39%; avoids guidance for FY21
- ❑ Astec Lifesciences strong results

- ❑ **Govt expects FY21 direct tax collections to fall short by about Rs 3 lakh cr:** Due to the nationwide lockdown imposed to tackle the outbreak of novel coronavirus, or COVID-19, the Centre expects to miss its gross direct tax collection budget target by around Rs 3 lakh crore in FY21. For the current fiscal, the Central Board of Direct Taxes (CBDT) has set a tax target of Rs 13.19 lakh crore.
- ❑ **PM Modi On Employment Generation:** As lockdowns to contain the coronavirus hit businesses around the world, the job market is changing by the day. Addressing the situation, PM Modi, who was meeting bureaucrats and technical experts today, said that the need of the hour was to focus on providing sustainable employment by reskilling and upskilling the current workforce. The Prime Minister said that for sustainable employment, skill development was the key to providing industries with adequate manpower as presently there were gaps in this regard. "There is a mismatch of skills in the country. Companies are not able to find the right personnel for the jobs they have to offer. Also, those who have talent, aren't getting adequate offers," Modi added.
- ❑ **Larsen & Toubro Q1FY21:** The company's net profit in Q1FY21 declined 79.4 percent to Rs 303 crore from Rs 1,472.6 crore while revenue fell 28.3 percent to Rs 21,260 crore from Rs 29,636 crore, YoY. EBITDA witnessed a decline of 47.2 percent to Rs 1,620.5 and operating margins saw a fall of 270 bps to 7.6 percent, YoY. L&T's order inflow fell 39 percent YoY to Rs 23,574 crore.
- ❑ **Heidelberg Cement Q1FY21** Revenue down 31% to Rs 407.7 crore Net profit down 38% to Rs 49 crore Ebitda down 31% to Rs 108.3 crore Ebitda margin flat at 26.6% Sales volumes down 31.9% to 857 KT Ebitda per tonne up 1% to Rs 1,264 Decrease in volumes impact revenue and profitability Lower volumes negatively impact operating leverage All numbers compared on a year-on-year basis
- ❑ **Astec LifeSciences Q1FY21** Revenue up 45.3% to Rs 111.9 crore Net profit of Rs 16.2 crore from net loss of Rs 1.1 crore Ebitda up 4.3 times to Rs 28.2 crore Ebitda margin at 25.2% from 8.4% Lower raw material costs aid margins All numbers are consolidated and compared on a year-on-year basis
- ❑ **Rallis India Q1FY21** Revenue up 6% to Rs 662.7 crore Net profit up 52% to Rs 91.9 crore Ebitda up 35% to Rs 128.3 crore Ebitda margin at 19.4% from 15.2% All numbers are consolidated and compared on a year-on-year basis Raw material cost as % of sales at 60.3% from 62.6% Lower raw material costs and other expenses aid margins Expect domestic demand to remain buoyant for crop care products.
- ❑ **Infosys:** Launched digital solution to re-skill the American workforce and fulfill employment needs following Covid-19.
- ❑ **Covid-19 Impact on Bajaj Auto:** All manufacturing operations came to a near standstill from 28 to 43 days between March and May. Able to ramp-up production to almost 70% of normal levels. However, things are far from normal as this is an unstable recovery due to sporadic local shutdowns in various parts of the country impacting both demand as well as supply chain.
- ❑ **Glenmark:** Phase-3 trial of Favipiravir demonstrates statistically significant faster time to clinical improvement with Favipiravir treatment in mild to moderate Covid-19 patients compared to control. It said that the medicine has a 40% faster clinical cure.

Red: Negative Impact **Green:** Positive Impact **Black :** Neutral.

ISEC 1QFY21 concall highlights:

ISEC 1QFY21

- Retail participation saw record high, many inactive client entered into the market and there was sharp rise in the new client in the industry.
- ISEC has diversified its sourcing channel. ICICIBANK contributed 65% of the sourcing against 80% last fiscal.
- There was increase of 90% average customer trading on daily basis.
- Scaled MTF & ESOP book to Rs 15 Bn against Rs 5.8 Bn in March 2020. Average MTF & ESOP book for the quarter was Rs 8.5 Bn with NIM range of 4-5%.
- Witnessed redemptions in the debt mutual fund whereas equity mutual fund saw gain in market share in terms of net flow. Also saw good traction in fixed income segment.
- Board revised the dividend distribution policy to payout of atleast 50% every year subject to some financial parameters.
- Employee expenses grew by 24% sequentially due to variable payout depending on performance of the company. Ratio of fixed to variable is 70:30. Other expenses declined due to bargain in transactional charges, digital driver franking charges to be lower and also last quarter there was Rs 9 Cr covid provisions which was not at this time. Covid provisions is not utilised till now and is sitting in the balance sheet.
- Management is planning to add US securities in the ICICIDIRECT platform to tap the opportunity.
- SBI and HDFC is the big contributor towards open architecture platform and there is no revenue share model with any banks other than ICICIBANK.
- I-Sec has moved to completely digital account opening process from mid-April and the run rate for new account opening has been steadily increasing with the June 2020 numbers being higher than June 2019 numbers.
- ISEC equity market share increased by 260 bps YoY to 10.7% whereas derivative market share went up by 150 bps YoY to 8.9%.
- Investment banking revenue was contributed mainly from block deal and QIP.

BAJAJ-AUTO 1QFY21 concall highlights:

- Demand: The Company has not seen any down trading. The quality of demand has not depreciated in this difficult period of COVID-19. The company's segment structuring is largely same to that of pre-covid period.
- Behavior of international markets is similar to that of India. In June 2020, restoration of demand in Motorcycles was there at about 75% YoY basis (previous year's level).
- July 2020 retail is already at 80-85% level. In this South Asia, Middle east and Latin are ahead whereas, Africa is slightly behind and same trend is expected to continue.
- Key countries: Nigeria, Philippines, Bangladesh, Egypt and Columbia is above normal. Uganda is below normal level. Demand in most of the countries' market is lying in between 75%-100% level and 10% below in CV levels.
- 3W demand in July 2020 reached at 20% of normal level in domestic demand and at 75% of normal level in international market's retail.
- Three wheeler's segment is substantially impacted due to lockdown and shared mobility's restoration is taking longer to recover to normalcy. Cargo segment is seeing some demand swift now.
- The commodity for the quarter has been adverse due to global prices going up.
- The company's forex contracts are well placed and rupees is expected to strengthen from here. Average exchange rate for 1QFY21 was Rs 75.6.
- Supply chain is very deep and wide across country & internationally and is present in 3 levels. Much of inter dependency is there among the suppliers so, disruption in one of them impacts the whole supply chain.
- Recent lockdown of 8 days in Aurangabad also impacted the company's supply side.
- For now, demand and supply are sort of balanced. In July 2020, first 10 days was pretty good around 90% of normal level. Post that lockdown was imposed in various cities that again hit the demand.
- Motorcycle Inventory is running below 30 days of current retail levels.
- Dealerships: 95% and 84% of the company's dealerships are open of Motorcycle and CV respectively.
- The company's current production level is at 65-75%.
- The company is targeting to reach 5 digit volume numbers in pro bike segment.
- KTM has bounced back very well in current quarter and share of loss is expected to come down drastically in 2QFY21.
- The company has taken price increase in 1QFY21. No major cost increase is expected in 2QFY21. Domestic motorcycle's gross margin is expected to improve marginally in 2QFY21.

APLLTD 1QFY21 CONCALL HIGHLIGHTS

- ❑ The US business grew by 73% YoY to Rs. 596 crs, sequentially grew by 3% with Sartans portfolio becoming more stabilized.
- ❑ For sartans- the company is present in 14 sartans (Constituting 40% of the 12 months sales in US)
- ❑ In the US, the Ophthalmics has been doing really good; the company has picked up good market share in. In Derma, the competition is quite high & the company is gradually ramping up.
- ❑ The strategy of the company is to lighten the balance sheet & invest in complex generics & 505(b)(2) products in the US market.
- ❑ Other international business grew by 62% YoY to Rs. 175 crs on account of increased growth from Europe & RoW on the lower base of previous quarter due to serialization issues. With serialization issues now being over, the company expects the Ex-US market to grow going ahead.
- ❑ API grew by 53% YoY to Rs. 264 crs on account Azithromycin API & other opportunities on account of China disruption. The company expects API to grow at around 15-20% for the full year.
- ❑ The company filed 8 ANDAs & received 6 approvals from the USFDA this quarter. Total 3 products were launched in this quarter, with 5 launches expected in 2QFY21. For the full year, the company expects to launch 15-20 products in US in FY21.
- ❑ The Domestic business declined by 6% YoY to Rs. 306 crs on account of strict lockdown in the month of April, May & parts of June. The portfolio of products in the India business saw some drags in specific areas of Liquid formulation segment, Hormones & Gynecology.
- ❑ Going ahead in the India business, the company expects to see improvement with good pickup in the monsoon, benefits flowing in through the changed strategy & strong uptick in the Azithromycin oral solids though Azithromycin liquids will see substantial drag.
- ❑ Other expenses has declined 5% YoY & 14% sequentially on account of lower travelling & promotional expenses, along with that the R&D spends were on the lower side impacted by Covid.

Plant details:

- F2 – OSD & Injectables plant (Oncology) - OSD block has been audited twice; for the Injectable plant, batches are ongoing with filings expected in the next 6 months.
- F3- General Injectables plant- Filed 3-4 products.
- F4- Jarod OSD plant- Expects to file batches in the next 6 months.
- ❑ The company expects to spend 700 crs in the next 1-2 yrs for expansion in the injectables & Jarod plant. The company also have some investment plans for the API segment.
- ❑ The gross debt for the company stands at Rs. 1439 crs, cash in hand at 260 crs.

IndiaMart Q1FY21 Webinar Highlights

- ❑ Currently running all time high buyer's traffic growth on weekly basis.
- ❑ Other income was higher during the quarter mainly on account of MTM gain on money invested in Debt mutual funds.
- ❑ 50% cost saving are temporary and reaming 50% are for the long period but come back to normal level once the business back to the normalcy.
- ❑ In May and June lot of people has looked for the Products and services on Internet which has led to increase in buyer's traffic.
- ❑ During the quarter around 15000 customers has not renewed the subscription. 80% are churned customers are from silver monthly pack.
- ❑ Management is believe that worst is behind in terms of customer churn and not except large churn going ahead. There will be little churn or small growth in customer base.
- ❑ 1/3 of the industry in economy is severely impacted due to covid-19 and management does not believe that the lost customers will come back immediately. But management expects to add new customers from the demanding industries.
- ❑ In this time of uncertainty, people are taking monthly or 6 monthly subscription.
- ❑ In general 2/3 collection is happened through filed sales and 1/3 through digital medium. Till now none of the company's office is open yet and management is not advising its sales force to go out on fields. Lately company has witness increase in digital payment.
- ❑ Profitability is not important for the next 2-3 months as company is focused on customer retention, servicing buyers and getting back the revenue.
- ❑ Collection in July will be in similar line to June.

TATAELXSI 1QFY21 Concall Highlights:

- ❑ Revenue for the quarter grew by 10.7% YoY and PBT also grew 33.9% YoY while QoQ saw a dip in performance due to COVID.
- ❑ Company's largest division product design division EPD grew by 13.2% YoY. Within EDP both media and communication business unit and medical and health care business unit recovered sharply during the quarter both sequentially and 20% upward YoY growth.
- ❑ Media and communication vertical grew 23% YoY and 3.3% QoQ.
- ❑ Medical and health care vertical grew by 26.5% YoY and 5.3% QoQ.
- ❑ Transportation vertical continues to be muted impacted both on our embedded product business and design business. Significant part of the IDV business is from the transportation segment.
- ❑ In transportation business both new deals as well as added new customers in this segment. However, the deal closure cycles have definitely become longer due to deal deferral, higher scrutiny and slowdown in decision making across value chain.
- ❑ Fall in revenue by 8% sequentially impacted the margins during the quarter. Additional expenses incurred 1QFY21 on employees as they were stuck in overseas location and they could not come back resulted to a sequential dip in profitability.
- ❑ Management control its operating cost by not adding any new office, no travel took place, etc. could help to control the operating cost.
- ❑ During COVID, lot of cost like travel, office space will continue to be muted which will be act as a cost control measure going ahead.
- ❑ Demand for auto segment is expected to be muted as per management. However, management is winning large deals with key customer yet further delayed for a quarter are so.
- ❑ Management is continue to remain optimistic auto segment while it is placing a bet correctly to that management is not completely depend on that segment.
- ❑ Broadcast and communication vertical top accounts is large multi-service operator based out of US. Business with this particular customer is growing over the last 12 years and management has warned significant deals, consolidation opportunity with these customers.

BULK DEAL


EXCHANGE	Date	SECURITY CODE	CLIENT NAME	DEAL TYPE	QUANTITY	PRICE
BSE	22-07-20	ACEMEN	UTASAV SUMANCHANDRA SHAH	B	17,050	17.96
BSE	22-07-20	AMFL	NAVEEN GUPTA	B	110,835	5.54
BSE	22-07-20	AMFL	NAVEEN GUPTA	S	110,835	5.64
BSE	22-07-20	AMFL	ROSHANI SUDARSHAN PALKAR	B	75,000	5.4
BSE	22-07-20	AMFL	CHANDRA GHOSH	S	275,110	5.57
BSE	22-07-20	AMFL	SAHADEVSINGHROWA	B	36,100	5.77
BSE	22-07-20	AMFL	SAHADEVSINGHROWA	S	144,713	5.63
BSE	22-07-20	AMFL	JINE ANIL VASWANI	B	100,000	5.65
BSE	22-07-20	AMFL	DEVABHAI NAGJIBHAI DESAI	B	325,238	5.57
BSE	22-07-20	AMFL	DEVABHAI NAGJIBHAI DESAI	S	325,238	5.64
BSE	22-07-20	DECCAN	BUSHRA MOHD FARHAN ATTARWALA	B	108,000	37.3
BSE	22-07-20	DECCAN	SALMA MOHAMMED RIZWAN ATTARWALA	B	108,000	37.3
BSE	22-07-20	NIRAJ	MALA SINHA	B	8,301	39.33
BSE	22-07-20	NIRAJ	MALA SINHA	S	233,196	39.1
BSE	22-07-20	ONTIC	MAHAVIRBHAI BABUBHAI TIWARI	B	130,000	7.03
BSE	22-07-20	ONTIC	VARSHABEN RAJNIKANT SHAH	S	210,730	7.03
BSE	22-07-20	PRISMEDI	MANISH NITIN THAKUR	B	57,807	12.26
BSE	22-07-20	SAGARPROD	TALISMAN SECURITIES PRIVATE LIMITED	B	300,000	10
BSE	22-07-20	SAGARPROD	SANJIB CHAKRABORTY	S	219,064	9.98
BSE	22-07-20	SHANGAR	MAHAVIRBHAI BABUBHAI TIWARI	S	21,000	43.9
BSE	22-07-20	SHANGAR	NIRAJ HARSUKHLAL SANGHAVI	B	30,000	43.9
BSE	22-07-20	SHANGAR	RANJANBEN BIPINCHANDRA MEHTA	B	46,086	43.9
BSE	22-07-20	SHANGAR	VIRTUE CERAMICS PRIVATE LIMITED .	S	79,536	43.9
BSE	22-07-20	SHANGAR	KHANAK BUDHIRAJA	B	30,000	43.9
BSE	22-07-20	VIKASMCORP	AVIATOR GLOBAL INVESTMENT FUND	B	5,950,000	8.6

Corporate Action


EXCHANGE	SECURITY CODE	SECURITY NAME	EX- DATE	PURPOSE	RECORD DATE
BSE	532742	PAUSHAKLTD	24-07-20	Final Dividend - Rs. - 6.0000	-
BSE	506605	POLYCHEM	24-07-20	Dividend - Rs. - 12.5000	-
BSE	532531	STAR	24-07-20	Final Dividend - Rs. - 2.0000	27-07-20
BSE	500251	TRENT	24-07-20	Dividend - Rs. - 1.0000	-

PARTICIPANT WISE OPEN INTEREST

Long Position




Short Position




MARKET MOVERS (1 MONTH CHANGE)

Nifty Movers



NSE Sectoral Indices Performance



Result Calendar Q4FY20

BSE Code	Company Name	Result Date	BSE Code	Company Name	Result Date
500410	ACC	20-Jul-20	532839	DISHTV	23-Jul-20
524663	BIBCL	20-Jul-20	526299	MPHASIS	23-Jul-20
533137	DEN	20-Jul-20	540173	PNBHOUSING	23-Jul-20
533012	LPDC	20-Jul-20	532497	RADICO	23-Jul-20
500266	MAHSCOOTER	20-Jul-20	500472	SKFINDIA	23-Jul-20
532650	MSPL	20-Jul-20	532374	STRTECH*	23-Jul-20
530367	NRBBEARING	20-Jul-20	526662	ARENTERP	23-Jul-20
512531	STCINDIA	20-Jul-20	500215	ATFL	23-Jul-20
500407	SWARAJENG	20-Jul-20	500150	FOSECOIND	23-Jul-20
532215	AXISBANK	21-Jul-20	507488	GMBREW	23-Jul-20
532978	BAJAJFINSV	21-Jul-20	541729	HDFCAMC	23-Jul-20
500034	BAJFINANCE	21-Jul-20	533192	KCPSUGIND	23-Jul-20
500092	CRISIL	21-Jul-20	532416	NEXTMEDIA	23-Jul-20
523367	DCMSHRIRAM	21-Jul-20	538772	NIYOGIN	23-Jul-20
531531	HATSUN	21-Jul-20	531879	PIONDIST	23-Jul-20
540777	HDFCLIFE	21-Jul-20	500405	SUPPETRO*	23-Jul-20
513599	HINDCOPPER	21-Jul-20	540762	TIINDIA	23-Jul-20
500696	HINDUNILVR	21-Jul-20	504067	ZENSARTECH	23-Jul-20
500188	HINDZINC	21-Jul-20	500425	AMBUJACEM	24-Jul-20
500184	HSCIL	21-Jul-20	500820	ASIANPAINT	24-Jul-20
540133	ICICIPRULI	21-Jul-20	500027	ATUL	24-Jul-20
532636	IIFL	21-Jul-20	519600	CCL	24-Jul-20
532756	MAHINDCIE	21-Jul-20	500110	CHENNPETRO	24-Jul-20
540719	SBILIFE	21-Jul-20	506395	COROMANDEL	24-Jul-20
539268	SYNGENE	21-Jul-20	539876	CROMPTON	24-Jul-20
500408	TATAELXSI	21-Jul-20	500171	GHCL	24-Jul-20
532633	ALLSEC	21-Jul-20	500875	ITC	24-Jul-20
532853	ASAHISONG	21-Jul-20	500228	JSWSTEEL	24-Jul-20
533543	BROOKS	21-Jul-20	500252	LAXMIMACH	24-Jul-20
532761	HOVS	21-Jul-20	505790	SCHAEFFLER	24-Jul-20
522034	SHANTIGEAR	21-Jul-20	505537	ZEEL	24-Jul-20
532310	SHREERAMA	21-Jul-20	501295	IITL	24-Jul-20
520151	SHREYAS	21-Jul-20	526668	KAMATHOTEL	24-Jul-20
505192	SMLISUZU	21-Jul-20	506184	KANANIIND	24-Jul-20
533573	APLLTD	22-Jul-20	540212	TCIEXP	24-Jul-20
532977	BAJAJ-AUTO	22-Jul-20	533164	TEXMOPIPES	24-Jul-20
500490	BAJAJHLDNG	22-Jul-20	532845	TGBHOTELS	24-Jul-20
500292	HEIDELBERG	22-Jul-20	505412	WENDT	24-Jul-20
532286	JINDALSTEL	22-Jul-20	532174	ICICIBANK	25-Jul-20
500510	LT	22-Jul-20	534091	MCX	25-Jul-20
532798	NETWORK18	22-Jul-20	533179	PERSISTENT	25-Jul-20
500355	RALLIS	22-Jul-20	509930	SUPREMEIND	25-Jul-20
532800	TV18BRDCST	22-Jul-20	522295	CONTROLPR	25-Jul-20
533138	ASTEC	22-Jul-20	521014	EUROTEXIND	25-Jul-20
532382	BALAJITELE	22-Jul-20	524226	GAEL	25-Jul-20
533272	CEBSCO	22-Jul-20	532305	INDSWFTLAB	25-Jul-20
532339	COMPUSOFT	22-Jul-20	524330	JAYAGROGN	25-Jul-20
507717	DHANUKA	22-Jul-20	532660	VIVIMEDLAB	25-Jul-20
508906	EVERESTIND	22-Jul-20	500049	BEL	27-Jul-20
541179	ISEC	22-Jul-20	517354	HAVELLS	27-Jul-20
500108	MTNL	22-Jul-20	534816	INFRATEL	27-Jul-20
540900	NEWGEN	22-Jul-20	531642	MARICO	27-Jul-20
540366	RADIOCITY	22-Jul-20	500680	PFIZER	27-Jul-20
507747	TTKHEALTH	22-Jul-20	503310	SWANENERGY	27-Jul-20
500002	ABB	23-Jul-20	532755	TECHM	27-Jul-20
540611	AUBANK	23-Jul-20	513349	AJMERA	27-Jul-20
532523	BIOCON	23-Jul-20	533047	IMFA	27-Jul-20

Economic Calendar					
Country	Monday 20th July 2020	Tuesday 21st July 2020	Wednesday 22nd July 2020	Thursday 23rd July 2020	Friday 24th July 2020
US			API Weekly Crude Oil Stock, Crude Oil Inventories, Existing Home Sales	Initial Jobless Claims	Manufacturing PMI, New Home Sales, U.S. Baker Hughes Oil Rig Count
UK/EUROPE				CBI Industrial Trends Orders	
INDIA					

Narnolia Financial Advisors Ltd. is a SEBI registered Research Analyst having SEBI Registration No. INH300006500. The Company/Analyst (s) does/do not have any holding in the stocks discussed but these stocks may have been recommended to clients in the past. Clients of Narnolia Financial Advisors Ltd. may be holding aforesaid stocks.

The stocks recommended are based on our analysis which is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed.

Disclosures: Narnolia Financial Advisors Ltd. (NFAL) (Formerly Microsec Capital Ltd.) is a SEBI Registered Research Analyst having registration no. INH300006500. NFAL is engaged in the business of providing Stock Broking, Depository Participant, Merchant Banking, Portfolio Management & distribution of various financial products. Details of associate entities of NFAL is available on the website at www.narnolia.com

No penalties have been levied on NFAL by any Regulatory/Statutory authority. NFAL, its associates, Research Analyst or their relative may have financial interest in the subject company. NFAL and/or its associates and/or Research Analyst may have beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report. NFAL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of NFAL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer, etc. in the subject company in the last 12 month period. NFAL and/or its associates may have received compensation from the subject company in the past 12 months. In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, NFAL or any of its associates may have: a) managed or co-managed public offering of securities from subject company of this research report, b) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report. d) Subject Company may have been a client of NFAL or its associates during 12 months preceding the date of distribution of the research report. NFAL and its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. NFAL and / or its affiliates may do and seek to do business including Investment Banking with companies covered in the research reports. As a result, the recipients of this report should be aware that NFAL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific Merchant Banking, Investment Banking or Brokerage service transactions. Research Analyst's views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of NFAL or its associates maintains arm's length distance with Research Team as all the activities are segregated from NFAL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement-

Analyst's ownership of the stocks mentioned in the Report	NIL
---	-----

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com.

Correspondence Office Address: Arch Waterfront, 5th Floor, Block GP, Saltlake, Sector 5, Kolkata 700 091; Tel No.: 033-40541700; www.narnolia.com.

Registered Office Address: Marble Arch, Office 201, 2nd Floor, 236B, AIC Bose Road, Kolkata 700 020; Tel No.: 033-4050 1500; www.narnolia.com

Compliance Officer: Manish Kr Agarwal, Email Id: mkagarwal@narnolia.com, Contact No.:033-40541700.

Registration details of Company: Narnolia Financial Advisors Ltd. (NFAL): SEBI Stock Broker Registration: INZ000166737 (NSE/BSE/MSEI); NSDL/CDSL: IN-DP-380-2018; Research Analyst: INH300006500, Merchant Banking: (Registration No.: INM000010791), PMS: (Registration No.: INP000002304), AMFI Registered Mutual Fund distributor: ARN 3087

Registration Details of Group entities: G. Raj & Company Consultants Ltd (G RAJ)-BSE Broker INZ260010731; NSDL DP: IN-DP-NSDL-371-2014 || Narnolia Commerce Limited (Formerly Microsec Commerce Ltd.)-MCX/NCDEX Commodities Broker: INZ000051636 || NarnoliaVeloX Advisory Ltd.- SEBI Registered PMS: INP000005109 || Eastwind Capital Advisors Pvt Ltd. (EASTWIND)-SEBI Registered Investment Adviser: INA300005439 || Narnolia Insurance Brokers Limited (Formerly Microsec Insurance Brokers Ltd.)-IRDA Licensed Direct Insurance Broker (Life & Non-Life) Certificate No. 134, License No. DB046/02 || Narnolia Securities Ltd. (NSL)-AMFI Registered Mutual Fund distributor: ARN 20558, PFRDA NPS POP: 27092018 || Narnolia Capital Advisors Pvt. Ltd. - RBI Registered NBFC:B.05.02568.

Disclaimer:

This report has been prepared by Narnolia Financial Advisors Ltd. (NFAL) and is meant for sole use by the recipient and not for public circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of NFAL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his/her/its own advisors to determine the merits and risks of such an investment. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NFAL will not treat recipients as customers by virtue of their receiving this report. Neither the Company, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits or lost opportunities that may arise from or in connection with the use of the information/report. The person accessing this information specifically agrees to exempt NFAL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold NFAL or any of its affiliates or employees responsible for any such misuse and further agrees to hold NFAL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NFAL & its group companies to registration or licensing requirements within such jurisdictions.